Cost-Effectiveness Analysis / Health Technology Assessment (CEA/HTA)

No progress


  • As a system, such as the current system in Japan, that heavily relies on cost per QALY to evaluate the value of a drug cannot appropriately appraise the drug value, additional factors should be incorporated in the appraisal.
  • The number of products assessed should be limited as Japan does not yet have a well-established HTA capability and at present is unable to assess a large number of products.
  • HTA should not restrict or delay patients’ access to new drugs.